vs
Columbia Financial, Inc.（CLBK）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Columbia Financial, Inc.的1.0倍（$69.8M vs $68.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 22.8%，领先361.2%），Columbia Financial, Inc.同比增速更快（29.7% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 17.7%）
哥伦比亚金融公司（CLBK）是一家美国多元化金融服务及银行控股企业，提供财富管理、资产管理、保险、年金、遗产规划在内的全方位金融规划产品与服务，满足客户不同阶段的财务规划需求。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CLBK vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.0倍
$68.8M
营收增速更快
CLBK
高出8.5%
21.2%
净利率更高
RIGL
高出361.2%
22.8%
两年增速更快
RIGL
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.8M | $69.8M |
| 净利润 | $15.7M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 28.6% | 33.2% |
| 净利率 | 22.8% | 384.0% |
| 营收同比 | 29.7% | 21.2% |
| 净利润同比 | 173.9% | 1769.2% |
| 每股收益（稀释后） | $0.15 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBKRIGL
| Q4 25 | $68.8M | $69.8M | ||
| Q3 25 | $67.3M | $69.5M | ||
| Q2 25 | $63.9M | $101.7M | ||
| Q1 25 | $58.8M | $53.3M | ||
| Q4 24 | $46.4M | $57.6M | ||
| Q3 24 | $54.3M | $55.3M | ||
| Q2 24 | $53.3M | $36.8M | ||
| Q1 24 | $49.7M | $29.5M |
净利润CLBKRIGL
| Q4 25 | $15.7M | $268.1M | ||
| Q3 25 | $14.9M | $27.9M | ||
| Q2 25 | $12.3M | $59.6M | ||
| Q1 25 | $8.9M | $11.4M | ||
| Q4 24 | $-21.2M | $14.3M | ||
| Q3 24 | $6.2M | $12.4M | ||
| Q2 24 | $4.5M | $-1.0M | ||
| Q1 24 | $-1.2M | $-8.2M |
毛利率CLBKRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CLBKRIGL
| Q4 25 | 28.6% | 33.2% | ||
| Q3 25 | 29.5% | 40.9% | ||
| Q2 25 | 25.8% | 60.1% | ||
| Q1 25 | 20.4% | 23.9% | ||
| Q4 24 | -57.6% | 28.9% | ||
| Q3 24 | 13.5% | 25.4% | ||
| Q2 24 | 9.0% | 1.2% | ||
| Q1 24 | -2.6% | -23.6% |
净利率CLBKRIGL
| Q4 25 | 22.8% | 384.0% | ||
| Q3 25 | 22.1% | 40.2% | ||
| Q2 25 | 19.3% | 58.6% | ||
| Q1 25 | 15.1% | 21.5% | ||
| Q4 24 | -45.7% | 24.9% | ||
| Q3 24 | 11.4% | 22.5% | ||
| Q2 24 | 8.5% | -2.8% | ||
| Q1 24 | -2.3% | -27.9% |
每股收益（稀释后）CLBKRIGL
| Q4 25 | $0.15 | $14.11 | ||
| Q3 25 | $0.15 | $1.46 | ||
| Q2 25 | $0.12 | $3.28 | ||
| Q1 25 | $0.09 | $0.63 | ||
| Q4 24 | $-0.20 | $0.82 | ||
| Q3 24 | $0.06 | $0.70 | ||
| Q2 24 | $0.04 | $-0.06 | ||
| Q1 24 | $-0.01 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $340.8M | $155.0M |
| 总债务越低越好 | $1.2B | $52.5M |
| 股东权益账面价值 | $1.2B | $391.5M |
| 总资产 | $11.0B | $513.6M |
| 负债/权益比越低杠杆越低 | 1.02× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CLBKRIGL
| Q4 25 | $340.8M | $155.0M | ||
| Q3 25 | $253.4M | $137.1M | ||
| Q2 25 | $248.2M | $108.4M | ||
| Q1 25 | $256.1M | $77.1M | ||
| Q4 24 | $289.2M | $77.3M | ||
| Q3 24 | $283.5M | $61.1M | ||
| Q2 24 | $391.1M | $49.1M | ||
| Q1 24 | $373.5M | $49.5M |
总债务CLBKRIGL
| Q4 25 | $1.2B | $52.5M | ||
| Q3 25 | $1.3B | $60.0M | ||
| Q2 25 | $1.3B | $60.0M | ||
| Q1 25 | $1.1B | $60.0M | ||
| Q4 24 | $1.1B | $60.0M | ||
| Q3 24 | $1.4B | $60.0M | ||
| Q2 24 | $1.7B | $60.0M | ||
| Q1 24 | $1.5B | $60.0M |
股东权益CLBKRIGL
| Q4 25 | $1.2B | $391.5M | ||
| Q3 25 | $1.1B | $117.6M | ||
| Q2 25 | $1.1B | $81.9M | ||
| Q1 25 | $1.1B | $18.6M | ||
| Q4 24 | $1.1B | $3.3M | ||
| Q3 24 | $1.1B | $-14.6M | ||
| Q2 24 | $1.0B | $-29.9M | ||
| Q1 24 | $1.0B | $-31.7M |
总资产CLBKRIGL
| Q4 25 | $11.0B | $513.6M | ||
| Q3 25 | $10.9B | $242.5M | ||
| Q2 25 | $10.7B | $206.7M | ||
| Q1 25 | $10.6B | $176.0M | ||
| Q4 24 | $10.5B | $164.0M | ||
| Q3 24 | $10.7B | $139.4M | ||
| Q2 24 | $10.8B | $128.4M | ||
| Q1 24 | $10.6B | $126.5M |
负债/权益比CLBKRIGL
| Q4 25 | 1.02× | 0.13× | ||
| Q3 25 | 1.11× | 0.51× | ||
| Q2 25 | 1.14× | 0.73× | ||
| Q1 25 | 1.01× | 3.23× | ||
| Q4 24 | 1.00× | 18.25× | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 1.47× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $68.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | — |
| 自由现金流率自由现金流/营收 | 85.1% | — |
| 资本支出强度资本支出/营收 | 14.3% | — |
| 现金转化率经营现金流/净利润 | 4.36× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $95.1M | — |
8季度趋势，按日历期对齐
经营现金流CLBKRIGL
| Q4 25 | $68.4M | $22.0M | ||
| Q3 25 | $31.0M | $24.0M | ||
| Q2 25 | $14.6M | $30.5M | ||
| Q1 25 | $-1.6M | $-893.0K | ||
| Q4 24 | $33.3M | $14.5M | ||
| Q3 24 | $-28.3M | $21.7M | ||
| Q2 24 | $18.6M | $302.0K | ||
| Q1 24 | $14.1M | $-5.0M |
自由现金流CLBKRIGL
| Q4 25 | $58.6M | — | ||
| Q3 25 | $28.1M | — | ||
| Q2 25 | $12.9M | — | ||
| Q1 25 | $-4.5M | — | ||
| Q4 24 | $25.9M | — | ||
| Q3 24 | $-31.1M | — | ||
| Q2 24 | $17.2M | — | ||
| Q1 24 | $12.5M | — |
自由现金流率CLBKRIGL
| Q4 25 | 85.1% | — | ||
| Q3 25 | 41.8% | — | ||
| Q2 25 | 20.2% | — | ||
| Q1 25 | -7.6% | — | ||
| Q4 24 | 55.7% | — | ||
| Q3 24 | -57.3% | — | ||
| Q2 24 | 32.3% | — | ||
| Q1 24 | 25.1% | — |
资本支出强度CLBKRIGL
| Q4 25 | 14.3% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 3.4% | — |
现金转化率CLBKRIGL
| Q4 25 | 4.36× | 0.08× | ||
| Q3 25 | 2.08× | 0.86× | ||
| Q2 25 | 1.19× | 0.51× | ||
| Q1 25 | -0.18× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | -4.57× | 1.75× | ||
| Q2 24 | 4.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
